{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=8&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Aurora",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 7434,
    "total_pages": 744,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=9&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=7&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T17:01:30.010Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia",
        "B Lymphoblastic Lymphoma",
        "Central Nervous System Leukemia",
        "Mixed Phenotype Acute Leukemia",
        "Testicular Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Calaspargase Pegol",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "365 Days",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "365 Days to 25 Years"
      },
      "enrollment_count": 5951,
      "start_date": "2019-10-31",
      "completion_date": "2032-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 203,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959085"
    },
    {
      "nct_id": "NCT01395017",
      "title": "Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2011-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-08",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395017"
    },
    {
      "nct_id": "NCT05335590",
      "title": "Adherence and Clinical Correlates in Persons With HIV on TAF",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 384,
      "start_date": "2022-04-25",
      "completion_date": "2026-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335590"
    },
    {
      "nct_id": "NCT04740476",
      "title": "An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "zorevunersen (STK-001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stoke Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Months and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-01-20",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740476"
    },
    {
      "nct_id": "NCT00339040",
      "title": "Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo/QHPV",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "7 Years to 12 Years"
      },
      "enrollment_count": 130,
      "start_date": "2006-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 32,
      "location_summary": "Alhambra, California • Long Beach, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00339040"
    },
    {
      "nct_id": "NCT00529568",
      "title": "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2007-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529568"
    },
    {
      "nct_id": "NCT07883590",
      "title": "A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Cytochrome P-450 Enzyme System"
      ],
      "interventions": [
        {
          "name": "LY3873862",
          "type": "DRUG"
        },
        {
          "name": "CYP450 Drug Cocktail",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-11",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Aurora, Colorado • Kansas City, Kansas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07883590"
    },
    {
      "nct_id": "NCT02713347",
      "title": "Advancing Symptom Alleviation With Palliative Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure",
        "Pulmonary Disease, Chronic Obstructive",
        "Emphysema",
        "Pulmonary Fibrosis, Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "ADAPT Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 306,
      "start_date": "2016-09-01",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02713347"
    },
    {
      "nct_id": "NCT01754038",
      "title": "Registry for Integrative Medicine Interventions Effectiveness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Conditions of Integrative Medicine Clinic Patients"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "BraveNet",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5069,
      "start_date": "2013-08",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • San Francisco, California • Santa Monica, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01754038"
    },
    {
      "nct_id": "NCT04848480",
      "title": "A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "insulin icodec",
          "type": "DRUG"
        },
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 582,
      "start_date": "2021-04-30",
      "completion_date": "2022-12-02",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-11-01T17:01:30.010Z",
      "location_count": 42,
      "location_summary": "Concord, California • Escondido, California • Fresno, California + 36 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04848480"
    }
  ]
}